Suraj Kalia
Stock Analyst at Oppenheimer
(3.79)
# 660
Out of 5,149 analysts
91
Total ratings
46.15%
Success rate
11.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Downgrades: Perform | n/a | $26.26 | - | 3 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $150 → $175 | $148.00 | +18.24% | 12 | Feb 25, 2026 | |
| PODD Insulet | Maintains: Outperform | $365 → $300 | $241.84 | +24.05% | 1 | Feb 19, 2026 | |
| ATRC AtriCure | Downgrades: Perform | n/a | $31.46 | - | 8 | Feb 18, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $140 → $132 | $113.61 | +16.19% | 2 | Jan 23, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $125 → $100 | $73.85 | +35.41% | 1 | Jan 16, 2026 | |
| INSP Inspire Medical Systems | Upgrades: Outperform | $175 | $65.80 | +165.96% | 3 | Dec 8, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $23 → $18 | $12.88 | +39.75% | 7 | Nov 19, 2025 | |
| EW Edwards Lifesciences | Downgrades: Perform | n/a | $85.28 | - | 6 | Oct 8, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $17.95 | +22.56% | 1 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $120 | $125.85 | -4.65% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $38.62 | -17.14% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $90 → $93 | $107.85 | -13.77% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.94 | +102.43% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $3.75 | +246.67% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $86.75 | +55.62% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $258.28 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $29.86 | +0.47% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $0.85 | +23,429.41% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $78.13 | +24.15% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $20.17 | +38.82% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $3.68 | +22.28% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.07 | +1,395.33% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $497.42 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $2.59 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $19.03 | +425.49% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $73.08 | - | 5 | Sep 12, 2018 |
PROCEPT BioRobotics
Feb 26, 2026
Downgrades: Perform
Price Target: n/a
Current: $26.26
Upside: -
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $150 → $175
Current: $148.00
Upside: +18.24%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $365 → $300
Current: $241.84
Upside: +24.05%
AtriCure
Feb 18, 2026
Downgrades: Perform
Price Target: n/a
Current: $31.46
Upside: -
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $140 → $132
Current: $113.61
Upside: +16.19%
Boston Scientific
Jan 16, 2026
Maintains: Outperform
Price Target: $125 → $100
Current: $73.85
Upside: +35.41%
Inspire Medical Systems
Dec 8, 2025
Upgrades: Outperform
Price Target: $175
Current: $65.80
Upside: +165.96%
Varex Imaging
Nov 19, 2025
Maintains: Outperform
Price Target: $23 → $18
Current: $12.88
Upside: +39.75%
Edwards Lifesciences
Oct 8, 2025
Downgrades: Perform
Price Target: n/a
Current: $85.28
Upside: -
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $17.95
Upside: +22.56%
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $125.85
Upside: -4.65%
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $38.62
Upside: -17.14%
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $107.85
Upside: -13.77%
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $4.94
Upside: +102.43%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $3.75
Upside: +246.67%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $86.75
Upside: +55.62%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $258.28
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $29.86
Upside: +0.47%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $0.85
Upside: +23,429.41%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $78.13
Upside: +24.15%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $20.17
Upside: +38.82%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $3.68
Upside: +22.28%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $1.07
Upside: +1,395.33%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $497.42
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $2.59
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $19.03
Upside: +425.49%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $73.08
Upside: -